Ozempic and its weight-loss cousin, Wegovy, outperform another longstanding weight-loss drug that targets the same hormone associated with blood sugar and appetite, a new study finds. Ozempic and Wegovy (semaglutide) promoted the loss of 10% or more body weight in 61% of people being treated for obesity and 23% being treated for diabetes after a year on the drugs, researchers reported Sept. 13 in the journal JAMA Network Open. By comparison, Saxenda (liraglutide) prompted similar weight loss in only 29% of those being treated for obesity and 12% being treated for type 2 diabetes. Studies have shown that losing 10% or more of body weight provides clinically significant health benefits, researchers said. This sort of weight loss can improve blood sugar levels and even put diabetes into remission for some, according to the National Institutes of Health. It can also improve cholesterol levels and promote heart health. “We found that long-term weight reduction varied significantly based on the medication’s active agent, treatment indication, dosage and persistence with the medication,” said lead investigator Hamlet Gasoyan, a researcher with the Cleveland Clinic’s Center for Value-Based Care Research. The study was funded by the National Cancer Institute.  Liraglutide was approved by the U.S. Food and Drug Administration in 2010 to treat type 2 diabetes and in 2014 to treat obesity. Semaglutide is more recent, having received approval in…  read on >  read on >

Initially approved to treat type 2 diabetes, Ozempic and Mounjaro also can help people with type 1 diabetes lose weight and control their blood sugar levels, a new study finds. Overweight or obese type 1 diabetics taking Mounjaro were able to reduce the amount of daily insulin they needed, researchers reported Thursday at the European Association for the Study of Diabetes annual meeting in Madrid. And both drugs helped patients lose weight, which can improve blood sugar control, researchers said. Ozempic (semaglutide) and Mounjaro (tirzepatide) help the body produce more insulin when needed — something that won’t help type 1 diabetics, who have lost the ability to produce any insulin. However, the drugs also slow down digestion of food and reduce the amount of glucose produced by the liver, both of which should help some type 1 diabetics control blood sugar levels, researchers said. “Some of the mechanisms through which semaglutide and tirzepatide lower blood sugar in type 2 diabetes are also likely to be relevant in type 1 diabetes,” said lead researcher Janet Snell-Bergeon, a professor with the University of Colorado Anschutz Medical Campus. For this study, researchers analyzed medical data for 100 adults with type 1 diabetes, half of whom where prescribed Ozempic and the other half Mounjaro. Both drugs prompted weight loss. Type 1 diabetics lost an average of 9% of their…  read on >  read on >

Humans could learn a few medical tips from their gorilla cousins, a new study says. Four plants used by wild gorillas in Gabon have antibacterial and antioxidant properties, researcher reported Sept. 11 in the journal PLOS One. Wild great apes often self-medicate, consuming medicinal plants that can treat their ailments, researchers said. Observing gorillas, researchers identified four native plant species they regularly use: the fromager tree (Ceiba pentandra), giant yellow mulberry (Myrianthus arboreus), African teak (Milicia excelsa) and fig trees (Ficus). The bark of all four plants demonstrated antibacterial activity against at least one antibiotic-resistant strain of E. coli, researchers discovered in lab tests. One in particular, the fromager tree, showed “remarkable activity” against all tested E. coli strains. All four plants also contain compounds that have medicinal effects, including phenols, alkaloids, flavonoids and proanthocyanidins, researchers said. Interviews with 27 people living in a nearby village found that these plants are used in local traditional medicine, the researchers added. Biodiverse regions like central Africa are home to a huge reservoir of potentially medicinal plants, researchers said. By paying attention to wild great apes, humans might be able to find new means of combatting antibacterial-resistant germs. “Alternative medicines and therapies offer definite hope for the resolution of many present and future public health problems,” wrote the research team led by senior investigator Sylvain Godreuil, a professor…  read on >  read on >

An ingredient in the hair dye a French woman used caused her to develop a vision-robbing retinopathy, researchers report. When she switched to a dye without these ingredients, called aromatic amines, her vision troubles resolved, according to a team led by Dr. Nicolas Chirpaz, an ophthalmologist at Edouard Herriot Hospital, in Lyon. Such cases could be rare, the researchers said, but spreading awareness of the danger “may allow prompt consideration to remove exposure to such hair dye” so eyes aren’t permanently damaged, Chirpaz and colleagues said. They published their case report Sept. 12 in the journal JAMA Ophthalmology. As the French team noted, this isn’t the first time hair dye has been linked to retinopathy: Three prior cases were reported in 2022 among “middle-aged women following exposure to hair dyes containing aromatic amines.” In the latest case, a 61-year-old woman with no prior history of vision trouble came to doctors with progressively blurry vision in both eyes “a few days after dyeing her hair with hair dye containing aromatic amines,” Chirpaz’ group said. The aromatic amine in the dye used in this case was para-phenylenediamine. Upon examination, the woman was found to have multiple retinal detachments that resembled the damage that can occur in retinopathies that are tied to certain enzymes found in the eye, called MEK1 or MEK2. The woman’s eyes also displayed an…  read on >  read on >

Prescriptions for amphetamine stimulants to treat ADHD have increased significantly in recent years, particularly during the pandemic. Unfortunately, high doses of stimulants like Adderall can increase the risk of psychosis or mania by more than fivefold, a new study finds. Patients had a nearly 63% increased risk of psychosis or mania if they took any prescription amphetamine within the past month, researchers reported Sept. 12 in the American Journal of Psychiatry. Those on heavy doses of amphetamines were at even greater peril of a psychotic episode, with an 81% increased risk, results show. The highest risk occurred in patients taking 30 milligrams or more of dextroamphetamine, which corresponds to 40 milligrams of Adderall, the study says. “Stimulant medications don’t have an upper dose limit on their labels, and our results show that it is clear that dose is a factor in psychosis risk and should be a chief consideration when prescribing stimulants,” said lead investigator Dr. Lauren Moran, a pharmacoepidemiology researcher at McLean Hospital in Belmont, Mass. “This is a rare but serious side effect that should be monitored by both patients and their doctors whenever these medications are prescribed,” Moran added. Moran said she pursued this study based on her experiences as an inpatient psychiatrist. She and her Mclean colleagues would regularly see patients experiencing their first episode of psychosis. Medical records would reveal…  read on >  read on >